S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Biden, GOP reach debt-ceiling deal, now Congress must approve it to prevent calamitous default
Sell every Stock except ONE (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Biden, GOP reach debt-ceiling deal, now Congress must approve it to prevent calamitous default
Sell every Stock except ONE (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Biden, GOP reach debt-ceiling deal, now Congress must approve it to prevent calamitous default
Sell every Stock except ONE (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Biden, GOP reach debt-ceiling deal, now Congress must approve it to prevent calamitous default
Sell every Stock except ONE (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
NYSE:BIO.B

Bio-Rad Laboratories (BIO.B) Competitors

$373.90
0.00 (0.00%)
(As of 05/26/2023 ET)
Compare
Today's Range
$373.90
▼
$373.90
50-Day Range
$373.90
▼
$467.95
52-Week Range
$373.90
▼
$467.95
Volume
6 shs
Average Volume
69 shs
Market Capitalization
$11.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media

BIO.B vs. BIO, AVTR, PKI, RVTY, TXG, PACB, ILMN, VTRS, TFX, and LEGN

Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Bio-Rad Laboratories (BIO), Avantor (AVTR), Revvity (PKI), Revvity (RVTY), 10x Genomics (TXG), Pacific Biosciences of California (PACB), Illumina (ILMN), Viatris (VTRS), Teleflex (TFX), and Legend Biotech (LEGN). These companies are all part of the "medical" sector.

Bio-Rad Laboratories vs.

Bio-Rad Laboratories (NYSE:BIO.B) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.

In the previous week, Bio-Rad Laboratories had 7 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 8 mentions for Bio-Rad Laboratories and 1 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.69 beat Bio-Rad Laboratories' score of -0.15 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Rad Laboratories
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bio-Rad Laboratories
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.80 billion3.95-$3.63 billion-$6.54-57.17
Bio-Rad Laboratories$2.78 billion4.04-$3.63 billion-$6.54-57.95

Bio-Rad Laboratories has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 64.3% of Bio-Rad Laboratories shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 17.1% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bio-Rad Laboratories received 223 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. Likewise, 64.80% of users gave Bio-Rad Laboratories an outperform vote while only 57.60% of users gave Bio-Rad Laboratories an outperform vote.

CompanyUnderperformOutperform
Bio-Rad LaboratoriesOutperform Votes
125
57.60%
Underperform Votes
92
42.40%
Bio-Rad LaboratoriesOutperform Votes
348
64.80%
Underperform Votes
189
35.20%

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories -7.01% 4.10% 2.91%
Bio-Rad Laboratories -7.01% 4.10% 2.91%

Bio-Rad Laboratories has a consensus target price of $653.00, indicating a potential upside of 72.30%. Given Bio-Rad Laboratories' higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Bio-Rad Laboratories beats Bio-Rad Laboratories on 10 of the 13 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIO.B vs. The Competition

Export to Excel
MetricBio-Rad LaboratoriesAnalytical instruments IndustryMedical SectorNYSE Exchange
Market Cap$11.07B$5.72B$4.58B$14.58B
Dividend YieldN/A0.42%2.44%4.11%
P/E Ratio-57.1715.51132.7520.72
Price / Sales3.9512.983,686.888.96
Price / Cash25.5873.5094.5622.93
Price / Book1.133.275.049.08
Net Income-$3.63B-$271.20M$118.58M$897.96M
7 Day PerformanceN/A1.06%1.09%1.43%
1 Month Performance-19.44%-1.99%1.28%-1.75%
1 Year PerformanceN/A-22.32%19.48%-10.31%

Bio-Rad Laboratories Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIO
Bio-Rad Laboratories
2.7384 of 5 stars		$382.56
-1.2%		$653.00
+70.7%		-30.7%$11.33B$2.80B-58.508,200Short Interest ↑
AVTR
Avantor
2.8153 of 5 stars		$20.88
+0.2%		$28.75
+37.7%		-37.4%$14.10B$7.51B22.7014,500Short Interest ↓
Positive News
PKI
Revvity
3.0162 of 5 stars		N/A$158.60
+∞		N/A$14.57B$3.31B15.0116,700Analyst Report
RVTY
Revvity
0 of 5 stars		$120.30
+0.0%		N/AN/A$15.09B$3.31B15.6616,700Analyst Report
News Coverage
TXG
10x Genomics
1.8849 of 5 stars		$53.32
-6.6%		$54.85
+2.9%		-0.2%$6.20B$516.41M-34.851,239Insider Selling
Gap Down
PACB
Pacific Biosciences of California
1.361 of 5 stars		$12.56
-3.8%		$12.75
+1.5%		+102.3%$3.14B$128.30M-9.04728Positive News
ILMN
Illumina
2.6502 of 5 stars		$204.37
-2.1%		$253.70
+24.1%		-24.1%$32.31B$4.58B-7.1610,260News Coverage
VTRS
Viatris
2.8613 of 5 stars		$9.24
-1.2%		$12.67
+37.1%		-25.6%$11.08B$16.26B5.8937,000Ex-Dividend
TFX
Teleflex
2.4613 of 5 stars		$237.27
-3.3%		$271.75
+14.5%		-19.9%$11.13B$2.79B30.9315,500
LEGN
Legend Biotech
1.7149 of 5 stars		$66.54
-3.5%		$78.89
+18.6%		+47.7%$10.98B$117M0.001,390Analyst Report
Analyst Revision
News Coverage

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NYSE:BIO.B) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -